Press release

Transgene Announces Upcoming Investor Meetings

20210412 - Transgene investor agenda EN

By nh|2021-04-12T16:13:10+02:00April 12th, 2021|Press release|Comments Off

Transgene presents initial Phase I data of TG6002, highlighting the potential of the intravenous administration of its oncolytic viruses

20210409 - TG6002 AACR EN

By nh|2021-04-08T16:13:42+02:00April 9th, 2021|Press release, TG6002, TG6002|Comments Off

Availability of Preparatory Documents for the Combined General Meeting of May 26, 2021

20210407 document AG EN

By nh|2021-04-07T15:21:16+02:00April 7th, 2021|Press release|Comments Off

Availability of Transgene’s 2020 Universal Registration Document

20210401 Transgene mise a disposition ddr 2020 EN

By nh|2021-04-01T16:57:49+02:00April 1st, 2021|Press release|Comments Off

Transgene expands Phase II clinical trial of therapeutic vaccine TG4001 in combination with avelumab versus avelumab monotherapy in patients with HPV16-positive anogenital cancers

20210310 Transgene TG4001 randomized Phase II EN

By nh|2021-03-10T16:23:07+01:00March 10th, 2021|Press release, TG4001, TG4001|Comments Off

Significant milestones achieved on all drug candidates in 2020 and financial visibility until 2022

20210310 Transgene Results 2020 EN

By nh|2021-03-10T15:37:34+01:00March 10th, 2021|Press release|Comments Off

Transgene to Present its Immuno-Oncology Expertise at Upcoming Scientific Conferences

20210302 - Transgene Scientific Conferences

By @CcR34Tg|2021-03-01T16:28:21+01:00March 2nd, 2021|Invir.IO, Myvac, Press release|Comments Off

Transgene and BioInvent have enrolled first patient in Phase I/IIa trial of novel oncolytic virus BT-001 in solid tumors

20210301 - Transgene BT-001 FPI - EN

By Lucie Larguier|2021-02-26T18:04:43+01:00March 1st, 2021|BT-001 (EN), Press release|Comments Off

First Head & Neck Cancer Patient Treated in France in a Phase I trial with TG4050 (myvac® Platform), Transgene’s Innovative Individualized Immunotherapy

20210121 TG4050 1st patient HNSCC EN

By nh|2021-01-20T14:41:47+01:00January 21st, 2021|Myvac, Press release, TG4050|Comments Off

Transgene and BioInvent receive approval from ANSM to proceed with Phase I/IIa trial of anti-CTLA4-armed oncolytic virus BT-001 in solid tumors

20210119 - ANSM Approval BT-001 EN

By nh|2021-01-18T16:39:17+01:00January 19th, 2021|BT-001, BT-001 (EN), Invir.IO, Press release|Comments Off

Privacy Overview

This website uses cookies to improve your experience while you browse the website. Of these, cookies categorized as necessary are stored on your browser as they are essential for the functioning of basic functionalities of the website. We also use third-party cookies which advise us to analyze and understand how you use this website. These cookies will only be stored in your browser with your consent. You also have the option of deactivating these cookies. But disabling some of these cookies may affect your browsing experience.

Necessary

Always Enabled

Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.

Cookie	Duration	Description
__cfduid	1 month	The cookie is used by cdn services like CloudFare to identify individual clients behind a shared IP address and apply security settings on a per-client basis. It does not correspond to any user ID in the web application and does not store any personally identifiable information.
viewed_cookie_policy	1 year	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.

Cookie	Duration	Description
_ga	1 an	This cookie is installed by Google Analytics. The cookie is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. The cookies store information anonymously and assign a randomly generated number to identify unique visitors.
_gat_gtag_UA_158044571_1	1 minute	Used to persist session state. More information: https://developers.google.com/analytics/devguides/collection/gtagjs/cookie-usage
_gid	1 day	This cookie is installed by Google Analytics. The cookie is used to store information of how visitors use a website and helps in creating an analytics report of how the wbsite is doing. The data collected including the number visitors, the source where they have come from, and the pages viisted in an anonymous form.
vuid	1 years	This domain of this cookie is owned by Vimeo. This cookie is used by vimeo to collect tracking information. It sets a unique ID to embed videos to the website.